Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine
Gianluca Masi1, Lorenzo Fornaro, Samanta Cupini
1UO Oncologia Medica 2 Universitaria, Ospedale Santa Chiara, Pisa, Italy. gl.masi@tin.it
Background:
A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung metastatic to the mediastinal lymph nodes and liver. She initially received a long-acting somatostatin analog (octreotide) and chemotherapy with cisplatin and etoposide, which was ineffective.
Investigations:
Physical examination, laboratory test, chromogranin A test, CT scan, (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scan, (18)F-FDG-PET scan, fine-needle and tissue core liver biopsies.
Diagnosis:
Pulmonary spindle-cell carcinoid tumor with metastases to mediastinal lymph nodes and liver.
Management:
Systemic treatment with oral capecitabine (1,500 mg/m(2) daily from day 1 to day 21) and intravenous liposomal doxorubicin (10 mg/m(2) on days 1, 8 and 15), both repeated every 4 weeks, administered concomitantly with long-acting octreotide 30 mg every 3 weeks. The patient achieved a significant and long-lasting response with the combination of capecitabine and liposomal doxorubicin. She reported no severe adverse effects.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists


